Searched for
GLP 1 DRUGS
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
- Yum Brands in exclusive talks to sell Pizza Hut to LongRange Capital, source saysYum Brands is reportedly in exclusive talks with private-equity firm LongRange Capital for a potential sale of its Pizza Hut chain. This mo...
- Bio Medica Laboratories shares to debut today. Here's what GMP suggests ahead of listingBio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- Eli Lilly’s obesity drug shows up to 30% weight loss in trialEli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...
- India’s protein boom runs into a whey crisis as prices surge 4X, shortages loomProtein-rich foods are becoming more expensive in India. Global supply issues and rising demand are pushing up the cost of whey, a key ingr...
- IT a tactical buy; Devarsh Vakil reveals 5 sectors worth buying as markets turn volatileLeading analyst Devarsh Vakil suggests Indian markets offer compelling buying opportunities now, with valuations correcting to attractive l...
- No cosmetic job with jabs, warns drug regulator CDSCOThe notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the...
- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
- Strait of Hormuz is now India's biggest market risk, says Ashi AnandIndian markets await clarity on Strait of Hormuz shipping. Ashi Anand of IME Capital suggests a defensive market approach. Oil prices near ...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Blackstone, CD&R explore bids for Ben & Jerry's owner MagnumPrivate equity firms Blackstone and CD&R are exploring bids for Magnum Ice Cream Company. Magnum was recently spun out of Unilever. The fir...
- Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarityEli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The...
- Hims earnings today: Why Hims & Hers Health stock dropped despite raising revenue forecast - here's what investors need to knowHims stock after Hims & Hers earnings: Hims & Hers Health shares dropped significantly after reporting a surprise first-quarter loss and re...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
Load More
